| Course Content |
Expand+Overview
Research within this research group involves research laboratories covering a wide spectrum of interests that include:
- fundamental science such as understanding of structure-function basis of novel therapeutic receptors in gene regulat...
Hide-Overview
Research within this research group involves research laboratories covering a wide spectrum of interests that include:
- fundamental science such as understanding of structure-function basis of novel therapeutic receptors in gene regulatory regions, the development of 2D and 3D cell systems to investigate cellular processes;
- applications such as the development of sensors, therapeutics, imaging and targeted delivery systems for anticancer, antimicrobial activity, or bone fracture repair; and
- current use such as informing the prescription of therapeutics.
The work is supported by local access to NMR spectroscopy, Mass Spectrometry, fluorescence imaging, single molecule imaging microscopies such as TEM and AFM, cell & tissue culture, animal facilities, chemical synthesis labs, and pharmaceutical formulation facilities among others.
Research Laboratories
Dr Mamoon Aldeyab and Dr Kathy Burnett work in Pharmacy Practice research, specifically in the (i) identification of antibiotic thresholds and, (ii) health promotion in community pharmacies.
Representative publications: A non-linear time-series analysis approach to identify thresholds in associations between population antibiotic use and rates of resistance. López-Lozano et al. Nature Microbiology (2019).
Professor Ibrahim Banat is interested in the production of biosurfactants for a variety of applications. Biosurfactants have roles in bacterial biofilms disruption on surfaces, have antimicrobial activity with potential roles in food products, wound healing, anticancer, and related applications.
Representative publications: Adjuvant antibiotic activity of acidic sophorolipids with potential for facilitating wound healing. Lydon, et al, Antimicrobial Agents and Chemotherapy. 5, (2017) e02547-16.
Dr Bridgeen Callan, Dr Murtaza Tambuwala, Dr Deborah Lowry, Dr Susan Hawthorne, and Professor Paul McCarron are interested in the development of smart delivery systems, formulation and development of sustained release, and the development of 2D and 3D systems to investigate cellular responses. These applications concern targeted delivery to eye, bone, lungs, and murine models of colitis, but also pancreatic cancer cells, skin cancer, colon cancer cells, and the difficult to work with neuroblastoma cells.
Representative publications: Electroneutral polymersomes for combined cancer chemotherapy. Aibani et al, Acta Biomaterialia, 80(2018)327-340; Intermittent hypoxia in obstructive sleep apnoea mediates insulin resistance through adipose tissue inflammation. Murphy et al. European Respiratory Journal 49 (2017) 1601731.
Professor John Callan & Prof Tony McHale are interested in the development of minimally invasive processes for targeted therapeutic applications. A significant part of their work involves organic synthesis to create microbubbles loaded with anti-cancer drugs that are administered intravenously, and then ruptured at the target site using ultrasonic energy. Current developments include targeting tumors in pancreatic cancer patients.
Representative publications: A versatile, stimulus-responsive nanoparticle-based platform for use in both sonodynamic and photodynamic cancer therapy. Nomikou et al. Acta Biomaterialia, 49(2017)414-421; Combined sonodynamic and antimetabolite therapy for the improved treatment of pancreatic cancer using oxygen loaded microbubbles as a delivery vehicle. McEwan et al., Biomaterials, 80(2016) 20-32.
Dr Mateus Webba da Silva is interested in understanding the structural basis for transcription regulation involving quadruple helix DNA, and the development of nucleic acid functional entities with applications in biomedicine.
Representative publications: Encoding Canonical DNA quadruplex structure. Dvorkin, et al. Science Advances,4, eaat3007 (2018).
Summary
Biomedical Science at Ulster University has an outstanding record of success in research, having been awarded the highest possible rating in RAE1996 and 2001, and ranked first place in terms of research power in RAE2008. In REF2014, we were judged to be among the top five universities in terms of research power (out of 92 UK submissions) with 100% four star rating for our research environment.
Biomedical Sciences research activities are currently organized within distinct Research Groups: Diabetes, Food & Health (through Nutrition Innovation Centre for Food and Health (NICHE)), Genomic Medicine, Pharmaceutical Sciences & Practice, Stratified Medicine and Vision Science.
Multi-disciplinary collaboration between the research groups is strongly encouraged and is widespread with research into, for instance, anti-diabetic and antioncogenic aspects of nutrition, the genomics of vitamin receptors, visual deterioration or cancer, imaging of neovascularisation. Our research investigates the interaction between cardiovascular disease and vision and the impact of health and disease, diet, diabetes on dementia, hypertension, vascular and inflammatory disease, to name a few.
The research groups collaborate both internally and internationally on a range of prioritized multi-disciplinary themes in functional foods, gene-nutrient interactions; pregnancy and early life; healthy ageing, musculoskeletal health; drug discovery and delivery, personalized medicine and genomic medicine. The BMSRI has strong collaborations with regional and global pharmaceutical and diagnostics companies and many of our graduates and postgraduates gain employment in the government bodies, pharma, diagnostics, and health care sectors as well as academia and through self-employment.
About
The Biomedical Sciences Research Institute (BMSRI) offers a “state-of-the-art” research environment for high profile researchers to undertake internationally agenda setting research in strategically prioritized areas of biomedicine. This research environment within Biomedical Sciences at Ulster has been continually judged as exceptional and world-leading and awarded the highest 100% ranking within the RAE2008, REF2014 and REF2021. Furthermore, in the Postgraduate Research Experience Survey (PRES) awards, it was ranked 2nd in the UK, with an overall satisfaction rate of 88%.
Our research is carried out in well-equipped laboratories allowing the latest methods to be applied to individual projects. Our infrastructure is managed as Core Facility Units (CFUs) with equipment and laboratories dedicated to supporting pre-clinical studies, controlled human trials with expertise in vascular research, advanced molecular bioimaging/microscopy, bioinformatics, cell technologies, cellular biology, chemical analysis, genomics, proteomics/metabolomics (including mass spectrometry & NMR analysis), ocular imaging and psychophysics, transgenics, physiology and pharmacology.
The BMSRI research infrastructure also includes centralized resources for: high throughput drug screening in vitro assays, clinical research & human intervention studies/ trials; the use and storage of mammalian cells and tissues; and in vivo studies and animal models that replicate human disease. The BMSRI uses its estate of equipment, specialist laboratories, infrastructure and internationally recognized biomedical expertise to offer clinical & translational services to Academic Researchers and Industrial Business partners. The BMSRI routinely engages in collaborative research with some of the world’s leading pharmaceutical and biomedical companies and through the support of Ulster’s Office of Innovation, the University has established a track record of success in the commercialization of its research outcomes.
Research within BMSRI frequently involves collaboration between clinicians, academics and businesses in the life and health sector contributing to the development and launch of innovative health technologies, medical devices, and therapeutics. In addition to high-spec capabilities such as human genome sequencing, flow-cytometry and tissue culture, the close proximity of our research centres to hospitals permits direct access to NHS diagnostic laboratories, Clinical staff, and expertise in research governance and healthcare economics.
|